Full Text View
Tabular View
No Study Results Posted
Related Studies
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
This study has been completed.
Study NCT00010400   Information provided by Office of Rare Diseases (ORD)

First Received on February 2, 2001.   Last Updated on June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Systemic Lupus Erythematosus
Antiphospholipid Antibody Syndrome
Additional conditions recognized in this trial
Antiphospholipid Syndrome
Lupus Erythematosus, Systemic
More general conditions related to this trial
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Interventions listed in this trial
Cyclophosphamide
filgrastim
Additional drug interventions recognized in this trial
Antibodies, Antiphospholipid
Lenograstim
More general drug interventions related to this trial
Adjuvants, Immunologic
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Johns Hopkins University


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services